Year End Report and Quarterly Report October - December 2016-01-01 - 2016-12-31

Q4 October-December

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -643 (-216).
  • Earnings per share: SEK -0.05 (-4.32).
  • Liquidity at the end of the period: kSEK 306 (84).

The period January-December

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -692 (-217).
  • Earnings per share: SEK -0.06 (-4.34).

CEO's statement
For Panion Animal Health, 2016 has been an exciting year. The field of gene therapy research and development shows exponential growth and we are determined to be part of that as one of the first companies with a veterinary focus. Our main project is a treatment for epilepsy in dogs, a serious disease that affects millions of family dogs across the world and for which medicine is not effective in approximately 30% of cases. We want to develop an effective gene therapy treatment that can alleviate or eliminate the scary and unpleasant seizure attacks and improve the quality of life for these dogs and their owners. Panion started the year as a subsidiary company of CombiGene AB under the name CombiGene Vet AB. During 2016, CombiGene decided to turn it into a separate company, changed the name to Panion Animal Health AB and distributed Panion's shares to CombiGene's shareholders on the 30th of September 2016.

Since I took over from the previous CEO in October, I have continued the structuring of the company and the development of its strategy for the future. On 30 November the new board was in place with an impressive collection of broad competencies and extensive experience in the field of veterinary science, medicine //pharmacology// and business. This, together with a management team of strong and enthusiastic directors, holds very good promise for a successful, targeted future.

In Q4, Panion's financial advisor started laying the necessary puzzle towards the acceptance of Panion on the stock market, so our shareholders can trade and our financial situation is clarified. In December we signed the important license agreement with CombiGene, giving Panion access to experimental study data, patents, and developments with the exclusive right to exploit and market the epilepsy product in dogs and cats within territories of the USA, Europe and Switzerland. Our plan is to use all the robust research performed and planned by CombiGene to move faster into the clinical studies in dogs, and we are actively reaching out to potential clinical investigators. We follow CombiGene's work closely and congratulate them on the progress towards a GMP-compliant production of the chosen drug candidate.

Several other projects have been identified as potential candidates for Panion's in-licensing strategy. We strongly believe in the future of gene therapy as the next major step forward for the pharmaceutical industry, and our focus will be on lifting relevant pre-clinical results from developments in human medicines back into the hungry field of veterinary medicines. Together with a fantastic team, I am excited to steer this racehorse into 2017.

Anja Holm
CEO,
Panion Animal Health AB (publ)

Future reporting date
Interim Report for Q1 2017, 29 May 2017.

For the complete Year End Report, see attached document.

For more information, please contact:
Anja Holm, CEO, DVM
+45 22 94 6 600
anja.holm@panion-animalhealth.com

About Panion
Panion Animal Health AB's aim is to develop and commercialize the canine application of CombiGene AB's technology for gene therapeutic treatment of drug refractory epilepsy. In addition, Panion aims at inlicensing or acquiring other, similar assets, i.e., animal health applications of human health development projects where relevant animal experiments can be lifted back into the veterinary field. Panion is a public Swedish company that started as a subsidiary company of CombiGene. The plan is to list Panion's shares during Spring 2017. Website: panion-animalhealth.com/

Nerladdningsbara filer

Information avseende budet från CombiGene

Styrelsen i Panion Animal Health mottog den 18 april ett bud på Panion Animal Health från CombiGene. Budet löpte ut den 20 juni (-19).


Påminnelse angående budet från CombiGene

Styrelsen i Panion Animal Health mottog den 18 april ett bud på Panion Animal Health från CombiGene. Budet löper ut den 20 juni (-19).





2019 Q1 report, Period January-March for Panion Animal Health AB

Period January-March

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -1 663 (-697).
  • Earnings per share: SEK -0,07 (-0,05).
  • Liquidity at the end of the period: kSEK 4 961 (2 708).

Styrelsen för Panion Animal Health AB (publ) ("Panion" eller "Bolaget") rekommenderar enhälligt aktieägarna och teckningsoptionsinnehavarna i Panion att acceptera CombiGenes offentliga erbjudande

Styrelsen för Panion Animal Health AB (publ) ("Panion" eller "Bolaget") rekommenderar enhälligt aktieägarna och teckningsoptionsinnehavarna i Panion att acceptera CombiGenes offentliga erbjudande


Kommuniké från årsstämma i Panion Animal Health AB (publ)

Idag, den 23 april 2019, hölls årsstämma i Panion Animal Health AB. Nedan följer en sammanfattning av de beslut som fattades vid årsstämman.


CombiGene lämnar ett offentligt uppköpserbjudande till innehavarna av aktier och teckningsoptioner av serie TO1 i Panion Animal Health

CombiGene AB (publ) ("CombiGene") har idag lämnat ett offentligt uppköpserbjudande till innehavarna av aktier ("Aktierna) och teckningsoptioner av serie TO1 med ISIN-kod SE0011205343 ("Teckningsoptionerna") i Panion Animal Health AB (publ) ("Panion" eller "Bolaget") att överlåta samtliga sina Aktier och Teckningsoptioner till CombiGene ("Erbjudandet"). Aktierna och Teckningsoptionerna är upptagna till handel på Spotlight Stock Market ("Spotlight").



Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
SE-102 45 Stockholm, Sweden

08-692 21 90

Om beQuoted